 Updated News | Heart Failure Patients With Preserved Ejection Fraction May Benefit From New ... Medical News Today LCZ696, a first-in-class compound, may improve treatment outcomes for half of all patients with heart failure, according to a Phase II clinical trial on heart failure patients with preserved ejection fraction; preserved ejection fraction is when all ... New Novartis drug shows potential in heart failure Phase II study of Novartis' drug LCZ696 reduces key predictor of morbidity ... LCZ696 demonstrates beneficial effects in heart failure patients with ... |
